No. 100001 Attach 100002 Attach 100003 Ko 100003 Varnametra 100003 Market 100003 Varnametra 100005 Attach 100005 Attach 100006 A	Multivessel Disease: I Limb Ischemia due a-inguinal mes of a Multicenter Platinum-Chromium se 2 Diabetic Patients rolled Trial
10005 Assuhiko Kawamoto LBC1-4 Late Breaking Clinical Trials (English) Coronary Artery Disease 10005 Assuhiko Kawamoto LBC1-3 Late Breaking Clinical Trials (English) Diabetes and Novel therapeutics 3/10(Fr) 9:30 1:120 3 Room 5 Novel Repembers Medicine Product, CLBS12 (HONEDRA&# 17-4), for the Treatment of Critic to Arteriosclerosis Obliterans and Buerger's Disease 10008 Noriaki Moriyama LBCS1-3 Late Breaking Cohort Studies (English) Structual Heart Disease and Emergency care 3/10(Fr) 13:30 15:05 3 Room 5 Novel Incremental Medicine Products Solitionary and Buerger's Disease 100010 Yo Iwata HI-5 Hot line (English) Cardiovascular Intervention and Vaccination 3/12(Sun) 8:00 9:50 5 Room 5 Retrospective Arabysis on Diameters of Drug-coated Ballions and Pre-dilatation Ballions in Intervention Intervention and Vaccination 3/12(Sun) 8:00 9:50 1 Room 5 Drug-Coated Ballions from Trials (English) 100013 Takashi Muramatsu LBCT2-3 Late Breaking Clinical Trials (English) Coronary Artery Disease 1 3/11(Sat) 15:25 17:15 3 Room 5 Praisuged Monotherapy after Percutaneous Coronary Intervention Coronary Syndrome (ASET-JapaNa 100014 Yu Kataoka LBCT1-2 Late Breaking Clinical Trials (English) Diabetes and Novel therapeutics 3/10(Fr) 9:30 11:20 2 Room 5 Praisuged Monotherapy after Percutaneous Coronary Syndrome (ASET-JapaNa 100014 Yu Kataoka LBCT1-2 Late Breaking Cohort Studies (English) Coronary Artery Disease 3/11(Sat) 10:30 12:05 3 Room 5 Praisuged Monotherapy after Percutaneous Coronary Syndrome (ASET-JapaNa 100014 Yu Kataoka LBCT2-1 Late Breaking Cohort Studies (English) Coronary Artery Disease 3/11(Sat) 10:30 12:05 3 Room 5 Praisuged Monotherapy after Percutaneous Coronary Syndrome (ASET-JapaNa 100014 Yu Kataoka LBCT2-1 Late Breaking Cohort Studies (English) Coronary Artery Disease 3/11(Sat) 10:30 12:05 3 Room 5 Praisuged Monotherapy after Percutaneous Coronary Syndrome (ASET-JapaNa 100014 Yu Masahita LBCT3-1 Late Breaking Cohort Studies (English) Coronary Artery Disease 3/11(Sat) 13:15 14:50 4 Room 5 Praisuged Monotherapy an</td><td>a-inguinal mes of a Multicenter Platinum-Chromium se 2 Diabetic Patients rolled Trial</td></tr><tr><td>100008 Noriaki Moriyama LBCS1-3 Late Breaking Cohort Studies (English) Structual Heart Disease and Emergency care 3/10(Fr) 13:30 15:05 3 Room 5 Long-term Assessment of Survival after Transcatcher Actic Valve Implication in Intervention and Vaccination 3/12(Sun) 8:00 9:50 5 Room 5 Retrospective Analysis on Diameters of Drug-coated Balloons and Pre-dilatation Balloons in Intervention and Vaccination 3/12(Sun) 8:00 9:50 5 Room 5 Retrospective Analysis on Diameters of Drug-coated Balloons and Pre-dilatation Balloons in Intervention Makes and Nakamura HL-1 Hot line (English) Cardiovascular Intervention and Vaccination 3/12(Sun) 8:00 9:50 1 Room 5 Retrospective Analysis on Diameters of Drug-coated Balloons and Pre-dilatation Balloons in Intervention Makes and Nakamura HL-1 Hot line (English) Cardiovascular Intervention and Vaccination 3/12(Sun) 8:00 9:50 1 Room 5 Retrospective Analysis on Diameters of Drug-coated Balloons and Pre-dilatation Balloons in Intervention Makes and Nakamura HL-1 Hot line (English) Cardiovascular Intervention and Vaccination 3/12(Sun) 8:00 9:50 1 Room 5 Retrospective Analysis on Diameters of Drug-coated Balloons and Pre-dilatation Balloons in Intervention Makes and Nakamura HL-1 Hot line (English) Cardiovascular Intervention and Vaccination 3/12(Sun) 8:00 9:50 1 Room 5 Retrospective Analysis on Diameters of Drug-coated Balloons and Pre-dilatation Balloons in Intervention Makes and Nakamura HL-1 Hot line (English) Cardiovascular Intervention and Vaccination 3/12(Sun) 8:00 9:50 1 Room 5 Retrospective Analysis on Diameters of Drug-coated Balloons and Pre-dilatation Balloons in Intervention Makes Analysis on Diameters of Drug-coated Balloons and Pre-dilatation Balloons in Intervention Analysis of Late Breaking Clinical Trials (English) Cardiovascular Intervention and Vaccination 3/12(Sun) 8:00 9:50 1 Room 5 Technoscoular Retrospective Analysis on Diameters of Drug-coated Balloons in Intervention Intervention Intervention Intervention and Vaccination 3/12(Sun) 8:00 9:50 1 Room 5 Technoscoular Ret</td><td>a-inguinal mes of a Multicenter Platinum-Chromium ne 2 Diabetic Patients rolled Trial</td></tr><tr><td>100010 Yo Iwata HL-5 Hot line (English) Cardiovascular Intervention and Vaccination 3/12(Sun) 8:00 9:50 5 Room 5 Retrospective Analysis on Diameters of Drug-coated Balloons and Pre-dilatation Balloons in Intervention and Waccination 3/12(Sun) 8:00 9:50 1 Room 5 Drug-Coated Balloons from the Treatment of Small Vessel Coronary Artery Disease: 1-Year Outcome Analysis on Diameters of Drug-Coated Balloons and Pre-dilatation Balloons in Intervention and Waccination 3/12(Sun) 8:00 9:50 1 Room 5 Drug-Coated Balloons from the Treatment of Small Vessel Coronary Artery Disease: 1-Year Outcome Analysis on Diameters of Drug-Coated Balloons and Pre-dilatation Balloons in Intervention with Biodegradable-Polymer Coronary Artery Disease: 1-Year Outcome Analysis on Diameters of Drug-Coated Balloons and Pre-dilatation Balloons in Intervention with Biodegradable-Polymer Representation With Coronary Artery Disease: 1-Year Outcome Analysis on Diameters of Drug-Coated Balloons and Pre-dilatation Balloons in Intervention with Biodegradable-Polymer Representation With Coronary Artery Disease: 1-Year Outcome Analysis on Diameters of Drug-Coated Balloons and Pre-dilatation Balloons in Intervention with Biodegradable-Polymer Presentation With Coronary Artery Disease: 1-Year Outcome Analysis on Diameters of Drug-Coated Balloons and Pre-dilatation Balloons and Pre-dilatation Balloons and Pre-dilatation Balloons in Intervention I</td><td>mes of a Multicenter Platinum-Chromium se 2 Diabetic Patients rolled Trial</td></tr><tr><td>Nakamura HL-1 Hot line (English) Cardiovascular Intervention and Vaccination 3/12(Sun) 8:00 9:50 1 Room 5 Endovascular Treatment. Nakamura HL-1 Hot line (English) Cardiovascular Intervention and Vaccination 3/12(Sun) 8:00 9:50 1 Room 5 Drug-Coated Balloons for the Treatment of Small Vessel Coronary Artery Disease: 1-Year Outo Randomized Non-Inferiority Trial 10013 Takashi Muramatsu LBCT2-3 Late Breaking Clinical Trials (English) Coronary Artery Disease 3/11(Sat) 15:25 17:15 3 Room 5 Prasugrel Monotherapy after Percutaneous Coronary Intervention with Biodegradable-Polymer Everoliments of Education State for Japanese Patients with Chronic Coronary Syndrome (ASET-JAPAM) 100014 Yu Kataoka LBCT1-2 Late Breaking Clinical Trials (English) Diabetes and Novel therapeutics 3/10(Fri) 9:30 11:20 2 Room 5 The Coronary Artery Disease: the Pre-specified Sub-analysis of the OPTIMAL Randomized Coronary Artery Disease: the Pre-specified Sub-analysis of the OPTIMAL Randomized Coronary Artery Disease: the Pre-specified Sub-analysis of the OPTIMAL Randomized Coronary Artery Disease: the Pre-specified Sub-analysis of the OPTIMAL Randomized Coronary Artery Disease: the Pre-specified Sub-analysis of the OPTIMAL Randomized Coronary Artery Disease: the Pre-specified Sub-analysis of the OPTIMAL Randomized Coronary Artery Disease: the Pre-specified Sub-analysis of the OPTIMAL Randomized Coronary Artery Disease Artery D</td><td>mes of a Multicenter Platinum-Chromium se 2 Diabetic Patients rolled Trial</td></tr><tr><td>Nakamura Nasaro Nakamura Nasaro Nasaro Nasaro Nakamura Nasaro Nasar</td><td>Platinum-Chromium se 2 Diabetic Patients rolled Trial</td></tr><tr><td>100013 lakasni Muramatsu LBC12-3 Late Breaking Clinical Trials (English) Coronary Artery Disease 3/11(Sat) 15:25 17:15 3 ROOM 5 Everolimus Eluting Stent for Japanese Patients with Chronic Coronary Syndrome (ASET-JAPAN 100014 Yu Kataoka LBCT1-2 Late Breaking Clinical Trials (English) Diabetes and Novel therapeutics 3/10(Fri) 9:30 11:20 2 Room 5 The Effect of Glucagon-like Peptide-1 Analogues on Atheroma Progression and Instability in 10:30 12:05 3 Room 5 With Coronary Artery Disease: the Per-specified Sub-analysis of the OPTIMAL Randomized Coronary Artery Disease: the Per-specified Sub-analysis of the OPTIMAL Randomized Coronary Artery Disease: the Per-specified Sub-analysis of the OPTIMAL Randomized Coronary Artery Disease: the Per-specified Sub-analysis of the OPTIMAL Randomized Coronary Artery Disease: the Per-specified Sub-analysis of the OPTIMAL Randomized Coronary Artery Disease 3/11(Sat) 12:05 3 Room 5 Impact of multidomain frailty on mode of death in elderly patients with heart failure: an extent FRACILE-HF 100019 Hideki Kitahara LBCS3-4 Late Breaking Cohort Studies (English) Coronary Artery Disease 3/11(Sat) 13:15 14:50 4 Room 5 Percutaneous Coronary Intervention 100020 Masahiro Yamawaki HL-6 Hot line (English) Cardiovascular Intervention and Vaccination 3/12(Sun) 8:00 9:50 6 Room 5 Predictors of incomplete stent apposition after percutaneous coronary intervention in bifurcation analysis of a randomized study: PROPOT- 100020 Shizuya Yamashita LBCT2-1 Late Breaking Clinical Trials (English) Coronary Artery Disease 3/11(Sat) 15:25 17:15 1 Room 5 Efficacy and Safety of Inclisiran in Japanese Patients with High Cardiovascular Risk and Elevated Patients with Coronary Propertive Bivaryashan and Wafarin Therapy in Real-World Patients with Coronary Propertive Bivaryashan and Wafarin Therapy in Real-World Patients with Coronary Propertive Bivaryashan and Wafarin Therapy in Real-World Patients with Coronary Propertive Bivaryashan and Wafarin Therapy in Real-World Patients with Coronary Propertive Bivaryashan a</td><td>e 2 Diabetic Patients rolled Trial</td></tr><tr><td>100017 Yuya Matsue LBCS2-3 Late Breaking Clinical Trials (English) Heart Failure 3/11(Sat) 10:30 12:05 3 Room 5 Impact of multidomain frailty on mode of death in elderly patients with heart failure: an exten FRAGILE-HF 100019 Hideki Kitahara LBCS3-4 Late Breaking Cohort Studies (English) Coronary Artery Disease 3/11(Sat) 13:15 14:50 4 Room 5 Dual Antithrombotic Therapy with Oral Anticoagulant and Prasugrel in Patients with Atrial Fibri Percutaneous Coronary Intervention 100020 Masahiro Yamawaki HL-6 Hot line (English) Cardiovascular Intervention and Vaccination 3/12(Sun) 8:00 9:50 6 Room 5 Predictors of incomplete stent apposition after percutaneous coronary intervention in bifurcation analysis of a randomized Study: PROPOT- 100022 Shizuya Yamashita LBCT2-1 Late Breaking Clinical Trials (English) Coronary Artery Disease 3/11(Sat) 13:15 14:50 5 Room 5 The Impact of COVID-19 Pandemic on the Emergency Cardiovascular Cares for Acute Myocard Patients with Coronary in Coronary Intervention Coronary in Coronary Intervention of the Emergency Cardiovascular Cares for Acute Myocard Patients with Coronary Intervention Rivaryaban and Warfarin Therapy in Real-World Patients with Coronary Intervention of Covid Patients with Coronary Intervention Rivaryaban and Warfarin Therapy in Real-World Patients with Coronary Intervention Rivaryaban and Warfarin Therapy in Real-World Patients with Coronary Intervention Rivaryaban and Warfarin Therapy in Real-World Patients with Coronary Intervention Rivaryaban and Warfarin Therapy in Real-World Patients with Coronary Intervention Rivaryaban and Warfarin Therapy in Real-World Patients with Coronary Intervention Rivaryaban and Warfarin Therapy in Real-World Patients with Coronary Rivaryaban and Warfarin Therapy in Real-World Patients with Coronary Rivaryaban and Warfarin Therapy in Real-World Patients with Coronary Rivaryaban and Warfarin Therapy in Real-World Patients with Coronary Rivaryaban and Warfarin Therapy in Real-World Patients with Coronary Rivaryaban Rivaryaban and Warfarin T</td><td>rolled Trial</td></tr><tr><td>Heart Failure 3/11(Sat) 10:30 12:05 3 Room 5 FRAGILE-HF 100019 Hideki Kitahara LBCS2-4 Late Breaking Cohort Studies (English) Coronary Artery Disease 3/11(Sat) 13:15 14:50 4 Room 5 Dual Antithrombotic Therapy with Oral Anticoagulant and Prasugrel in Patients with Atrial Fibrication and Vaccination 100020 Masahiro Yamawaki HL-6 Hot line (English) Cardiovascular Intervention and Vaccination 3/12(Sun) 8:00 9:50 6 Room 5 Predictors of incomplete stent apposition after percutaneous coronary intervention in bifurcation analysis of a randomized study: PROPOT- 100022 Shizuya Yamashita LBCT2-1 Late Breaking Clinical Trials (English) Coronary Artery Disease 3/11(Sat) 15:25 17:15 1 Room 5 Efficacy and Safety of Inclisiran in Japanese Patients with High Cardiovascular Risk and Elevate 100024 Mitsukuni Kimura LBCS3-5 Late Breaking Cohort Studies (English) Coronary Artery Disease 3/11(Sat) 13:15 14:50 5 Room 5 The Impact of COVID-19 Pandemic on the Emergency Cardiovascular Cares for Acute Myocard Prespective Rivarovaban and Warfarin Therapy in Real-World Patients with Coronary C</td><td>ed follow-up of</td></tr><tr><td>Hideki Kitahara LBCS3-4 Late Breaking Cohort Studies (English) Coronary Artery Disease 3/11(Sat) 13:15 14:50 4 Room 5 Percutaneous Coronary Intervention 100020 Masahiro Yamawaki HL-6 Hot line (English) Cardiovascular Intervention and Vaccination 3/12(Sun) 8:00 9:50 6 Room 5 Predictors of incomplete stent apposition after percutaneous coronary intervention in bifurcation analysis of a randomized study: PROPOT- 100022 Shizuya Yamashita LBCT2-1 Late Breaking Clinical Trials (English) Coronary Artery Disease 3/11(Sat) 15:25 17:15 1 Room 5 Efficacy and Safety of Inclisiran in Japanese Patients with High Cardiovascular Risk and Elevated Study Mitsukuni Kimura LBCS3-5 Late Breaking Cohort Studies (English) Coronary Artery Disease 3/11(Sat) 13:15 14:50 5 Room 5 The Impact of COVID-19 Pandemic on the Emergency Cardiovascular Cares for Acute Myocard Five-year Prospective Rivarovaban and Warfarin Therapy in Real-World Patients with Coronary Coronary Studies (English) Coronary Artery Disease Five-year Prospective Rivarovaban and Warfarin Therapy in Real-World Patients with Coronary Coronary Studies (English) Coronary Artery Disease Studies (English) Five-year Prospective Rivarovaban and Warfarin Therapy in Real-World Patients with Coronary Coronary Studies (English) Real-World Patients with Coronary Real-World Patients Real-</td><td></td></tr><tr><td>HIL-6 Hot line (English) Cardiovascular Intervention and Vaccination 3/12(Sun) 8:00 9:50 6 Room 5 analysis of a randomized study: PROPOT- 100022 Shizuya Yamashita LBCT2-1 Late Breaking Clinical Trials (English) Coronary Artery Disease 3/11(Sat) 15:25 17:15 1 Room 5 Efficacy and Safety of Inclisiran in Japanese Patients with High Cardiovascular Risk and Elevate 100024 Mitsukuni Kimura LBCS3-5 Late Breaking Cohort Studies (English) Coronary Artery Disease 3/11(Sat) 13:15 14:50 5 Room 5 The Impact of COVID-19 Pandemic on the Emergency Cardiovascular Cares for Acute Myocarc</td><td>ation After</td></tr><tr><td>100024 Mitsukuni Kimura LBCS3-5 Late Breaking Cohort Studies (English) Coronary Artery Disease 3/11(Sat) 13:15 14:50 5 Room 5 The Impact of COVID-19 Pandemic on the Emergency Cardiovascular Cares for Acute Myocarcular Cares for Acute Myocarcular Cares for Acute Myocarcular Cares Prospective Rivarovahan and Warfarin Therapy in Real-World Patients with Coronary</td><td>lesionsPost hoc</td></tr><tr><td>Five-year Prospective Rivarovahan and Warfarin Therapy in Real-World Patients with Coronary</td><td>LDL-C (ORION-15)</td></tr><tr><td>Five-year Proceeding Divarovahan and Warfarin Therapy in Deal-World Patients with Coronan</td><td>ıl Infarction in Japan</td></tr><tr><td>100026 Yukio Ozaki LBCS3-3 Late Breaking Cohort Studies (English) Coronary Artery Disease 3/11(Sat) 13:15 14:50 3 Room 5 Fibrillation, and Chronic Kidney Disease (CKD)</td><td>Stents, Atrial</td></tr><tr><td>100028 Raisuke lijima HL-2 Hot line (English) Cardiovascular Intervention and Vaccination 3/12(Sun) 8:00 9:50 2 Room 5 Sometime of the AFIRE study </td><td></td></tr><tr><td>100030 Kazuhisa Kaneda Kaneda</td><td>ect Oral</td></tr><tr><td>Ayumu Fujioka LBCT1-4 Late Breaking Clinical Trials (English) Diabetes and Novel therapeutics 3/10(Fri) 9:30 11:20 4 Room 5 A Multicenter Prospective Interventional Trial of Therapeutic Angiogenesis Using Bone Marrow Cells Implantation for Critical-Limb-Threatening-Ischemia Patients with Thromboangiitis Oblite</td><td></td></tr><tr><td>100035 Kotaro Nochioka LBCS2-1 Late Breaking Cohort Studies (English) Heart Failure 3/11(Sat) 10:30 12:05 1 Room 5 Ten-year Prognosis of Chronic Heart Failure in Japan: A Report from the CHART-2 Study</td><td></td></tr><tr><td>100036 Hiroshi Iwata LBCS3-2 Late Breaking Cohort Studies (English) Coronary Artery Disease 3/11(Sat) 13:15 14:50 2 Room 5 The Study of Real World Anticoagulation and Antiplatelet Practice in Patients with Acute Coron Complicated with Atrial fibrillation: STAR-ACS</td><td>y Syndrome</td></tr><tr><td>100038 Taku Inohara LBCS1-2 Late Breaking Cohort Studies (English) Structual Heart Disease and Emergency care 3/10(Fri) 13:30 15:05 2 Room 5 Transcatheter Aortic Valve Implantation for Dialysis Patients: Insights from the OCEAN-TAVI E</td><td>alysis Cohort</td></tr><tr><td>100039 Hiroki Shiomi LBCT2-5 Late Breaking Clinical Trials (English) Coronary Artery Disease 3/11(Sat) 15:25 17:15 5 Room 5 Ten-year Clinical Outcomes from a Randomized Trial Comparing New-generation Everolimus-expenses First-generation Sirolimus-eluting Stent</td><td>iting Stent Versus</td></tr><tr><td>100040 Ken Ishikura LBCS3-1 Late Breaking Cohort Studies (English) Coronary Artery Disease 3/11(Sat) 13:15 14:50 1 Room 5 Comparison of the Pre-Hospital 12-lead Electrocardiogram Transmission Protocol and the Pre-Notification Protocol for Patients with Acute Myocardial Infarction.</td><td>ospital Ambulance</td></tr><tr><td>100043 Yohei Ohno LBCS1-1 Late Breaking Cohort Studies (English) Structual Heart Disease and Emergency care 3/10(Fri) 13:30 15:05 1 Room 5 Outcomes of Transcatheter Aortic Valve Implantation for Failed Surgical Bioprosthesis: Insight TAVI TAV-in-SAV Cohort</td><td>From the OCEAN-</td></tr><tr><td>100045 Makoto Takei LBCS2-2 Late Breaking Cohort Studies (English) Heart Failure 3/11(Sat) 10:30 12:05 2 Room 5 Heart Failure with Small, Restrictive Heart: An Epidemiological Report from JROAD-HF</td><td></td></tr><tr><td>100047 Masahiko Asami LBCS1-4 Late Breaking Cohort Studies (English) Structual Heart Disease and Emergency care 3/10(Fri) 13:30 15:05 4 Room 5 Initial Japanese Multicenter Experience and Age-Related Outcomes Following Left Atrial Appendix from the OCEAN-LAAC Registry</td><td>age Closure: Insight</td></tr><tr><td>100048 Mike Saji LBCS2-5 Late Breaking Cohort Studies (English) Heart Failure 3/11(Sat) 10:30 12:05 5 Room 5 Acute results Following Transcatheter Edge-to-edge Repair with MitraClip: Insights From the Company of the</td><td>EAN-Mitral Registry</td></tr><tr><td>Takenobu Shimada LBCS1-5 Late Breaking Cohort Studies (English) Structual Heart Disease and Emergency care 3/10(Fri) 13:30 15:05 5 Room 5 Prognostic Risk Stratification after Out-of-hospital Cardiac Arrest by Using Pre-hospital Resuscing Analysis of All-Japan Utstein Registry Data</td><td>ition Features:</td></tr><tr><td>10050 Hideki Miyachi LBCS3-6 Late Breaking Cohort Studies (English) Coronary Artery Disease 3/11(Sat) 13:15 14:50 6 Room 5 Impact of the COVID-19 on Management of Patients with STEMI Underwent Primary PCI: Insign</td><td>its from Tokyo CCU</td></tr><tr><td>100054 Keiichi Hishikari LBCT2-2 Late Breaking Clinical Trials (English) Coronary Artery Disease 3/11(Sat) 15:25 17:15 2 Room 5 Effect of Evolocumab in End Stage Renal Disease Ratients with Polyvascular Disease after Perc</td><td>taneous Coronary</td></tr><tr><td>100056 Leo Hata LBCS2-4 Late Breaking Cohort Studies (English) Heart Failure 3/11(Sat) 10:30 12:05 4 Room 5 Genetic Testing for Hypertrophic Cardiomyopathy in the Real World: Results from the PREVAIL</td><td>HCM Registry</td></tr><tr><td>100057 Hiroki Niikura LBCT1-5 Late Breaking Clinical Trials (English) Diabetes and Novel therapeutics 3/10(Fri) 9:30 11:20 5 Room 5 Efficacy and Feasibility of Transcatheter Closure with Amplatzer Vascular Plug II for Japanese Paravalvular Leak</td><td>atients with Mitral</td></tr><tr><td>100061 Tatsuya Nakama LBCS1-6 Late Breaking Cohort Studies (English) Structual Heart Disease and Emergency care 3/10(Fri) 13:30 15:05 6 Room 5 Second-generation low-dose drug-coated balloon versus high-dose drug-coated balloon for syn femoropopliteal artery disease: the result from the PROSPECT-MONSTER study</td><td>accine with Pilt al</td></tr><tr><td>100063 Naotaka Okamoto HL-4 Hot line (English) Cardiovascular Intervention and Vaccination 3/12(Sun) 8:00 9:50 4 Room 5 A Direct Comparison of Rotational and Orbital Atherectomy for Calcified Lesions Guided by Option Tomography: DIRO Trial</td><td></td></tr></tbody></table>	

Abstract No.	First Name	Last Name	Program No.	Session	Session title	Date	Time	Order	Room	Abstract Title
110001	Elzbieta	Jasinska	HL-7	Hot line (English)	Cardiovascular Intervention and Vaccination	3/12(Sun)	8:00 9:50	7	Room 5	Impact of Ofatumumab on Immune Responses Post-vaccination in RMS Patients: ALITHIOS Vaccination Sub-study Design
110002	Shigeru	Saito	HL-3	Hot line (English)	Cardiovascular Intervention and Vaccination	3/12(Sun)	8:00 9:50	3	ROOM 5	Intravascular Lithotripsy for Vessel Preparation in Calcified Coronary Arteries Prior to Stent Placement: Japanese Disrupt CAD IV Study 2-year Results